The First CAR-T Drugs Have Left The Gate

For all the talk about biotechs being nimble, it's a big pharma that looks like it'll be the first company to launch a chimeric antigen receptor T-cell (CAR-T) product.

Novartis (NYSE:NVS) announced last week that the Food and Drug Administration accepted its application to market tisagenlecleucel-T, which used to be called CTL019, in patients with B-cell acute lymphoblastic leukemia (ALL) who are relapsed and refractory to other therapies. The application was given a priority review, meaning an approval decision should be made within six months.

Back to news